Neurons reprogrammed directly from the skin cells of people living with virally suppressed HIV carried a transcriptional signature not seen in neurons from matched donors without HIV, according to a study by Philipp Ostermann, Teresa Evering and colleagues at Weill Cornell Medicine and collaborating institutions, published in JCI Insight (posted online 1 December 2025, in the issue dated 23 January 2026). Dermal fibroblasts were taken from six people with chronic HIV-1 on antiretroviral therapy and viral loads below 50 copies per millilitre (ages 27 to 64, median 53, 83 percent male) and from seven age and sex matched people without HIV (ages 27 to 66, median 55, 71 percent male). Using the transcription factors NGN2 and ASCL1 over 21 days, the fibroblasts were converted into induced neurons, which were checked by immunocytochemistry, single cell RNA sequencing and electrical recordings. Bulk RNA sequencing found 29 genes significantly differently expressed between the two groups of neurons: 16 lower and 13 higher in cells from the HIV group.

The attraction of the method is that it sidesteps the central obstacle in the field: living brain tissue cannot be sampled, and post mortem brain studies have often lacked comparable donors without HIV. Unlike stem cell routes, direct reprogramming is reported to preserve donor age related features, and the authors' transcriptomic ageing analysis indicated those signatures were retained. HIV-associated neurocognitive impairment remains common in people whose virus is well controlled, and it is currently defined almost entirely by neuropsychological testing rather than by any cell or tissue measure.

Several of the genes have prior form in brain disease. Expression of SORCS1, a gene linked in genetic studies to Alzheimer's disease, was higher in neurons from the HIV group; COL23A1, whose variants have been associated with rate of cognitive decline in Alzheimer's disease and with memory performance, was more than eight-fold lower. DOC2B, involved in neurotransmitter release, was reduced about seven-fold on average, and DPP6, a potassium channel factor, was raised. IFI27, an interferon-stimulated gene, was higher in the HIV group, matching earlier findings in autopsy brain tissue from the NeuroAIDS Tissue Consortium. Expression of the FOXL2NB-FOXL2-LINC01391 locus was reduced and correlated inversely with neurocognitive impairment among the six participants with HIV.

The caveats are large and the authors state several of them. Thirteen donors is a very small sample, the correlation with cognitive test scores rests on six people, and the study writes explicitly that its size prevents conclusions about, for example, the effect of sex on SORCS1. Six of the 29 differences were also present in the matched unconverted fibroblasts, leaving 23 the authors treated as neuron specific. Cultured cells are not a brain, gene expression differences are not disease, and nothing here identifies a cause: people with long-standing HIV differ from controls in many ways besides the virus. No treatment or clinical test follows from this work.